Haofan Biotech announced that in the first half of 2026, it achieved operating income of 379 million yuan, a year-on-year increase of 40.30%; net profit attributable to shareholders of listed companies was 707.463 million yuan, a year-on-year decrease of 6.77%; net profit after deducting non-recurring profit and loss was 60.379 million yuan, a year-on-year decrease of 2.61%; and net cash flow from operating activities was 127 million yuan, an increase of 181.57% year on year. Basic earnings per share were $0.66, down 7.04% year over year. During the reporting period, no cash dividends will be distributed, bonus shares will not be given, and capital will not be transferred from the Provident Fund. The company's 2026 restricted stock incentive plan has been reviewed and approved by the shareholders' meeting.

Haofan Biotech announced that in the first half of 2026, it achieved operating income of 379 million yuan, a year-on-year increase of 40.30%; net profit attributable to shareholders of listed companies was 707.463 million yuan, a year-on-year decrease of 6.77%; net profit after deducting non-recurring profit and loss was 60.379 million yuan, a year-on-year decrease of 2.61%; and net cash flow from operating activities was 127 million yuan, an increase of 181.57% year on year. Basic earnings per share were $0.66, down 7.04% year over year. During the reporting period, no cash dividends will be distributed, bonus shares will not be given, and capital will not be transferred from the Provident Fund. The company's 2026 restricted stock incentive plan has been reviewed and approved by the shareholders' meeting.